Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS

NCT02419638 · clinicaltrials.gov ↗

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Collaborative decision between study PI and sponsor.

Conditions

Multiple Sclerosis

Interventions

DRUG: Rebif (IFN β-1a subcutaneous three times per week)
DRUG: Tecifdera (dimethyl fumarate)

Sponsor

Brigham and Women's Hospital

Collaborators

[object Object]